Is Amivantamab a targeted drug?

Amivantamab (Amivantamab) is a targeted drug that belongs to a class of biologic drugs designed to treat a specific type of lung cancer, non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations. In the case of evantumumab, its primary action is a dual-targeting mechanism. First, it targets EGFR mutations, a common molecular mutation in lung cancer that drives cancer cells to grow and divide abnormally. Secondly, evantumumab can also inhibit the MET signaling pathway, which is also related to the development of lung cancer. By interfering with these two key pathways simultaneously, evantumumab can effectively inhibit the growth and spread of lung cancer cells.